James Boylan

CEO

Christine Del Corsano

CFO

Edd Fleming

Executive Vice President, Commercialization

Robert Glassman MD

EVP, Search and Evaluation

Amar Patel

Vice President

1 past transactions

CAMP4 Therapeutics

Series B in 2022
CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start to disease treatment, significantly reducing the time and risk to bring new medicines to patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.